BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters
MWN-AI** Summary
BioStem Technologies, Inc. (OTC: BSEM), a prominent MedTech firm concentrating on placental-derived products for advanced wound care, has announced the acquisition of land for its new headquarters at the Research Park at Florida Atlantic University in Boca Raton, Florida. This significant step is part of the company's strategy to expand operations amid increasing demand for its innovative products. The City of Boca Raton has approved economic incentives worth up to $300,000 to support the creation of up to 100 jobs over the next five years as a result of this relocation.
The purchased four-acre parcel will house BioStem's administrative offices, manufacturing, and distribution facilities. Although a specific timeline for moving to the new site has not been disclosed, the company expresses enthusiasm about consolidating its operations in a technology-rich environment. Jason Matuszewski, Chairman and CEO of BioStem Technologies, emphasized the value of staying in South Florida, where the local life science sector continues to thrive. The Research Park offers access to a skilled workforce and advanced resources, positioning BioStem among other technological innovators and reputable academic institutions.
The Research Park, operational since 1985, serves as a collaborative hub for technology companies and research organizations. It provides essential support for companies aiming to innovate and expand their reach. Andrew S. Duffell, the park's president, highlighted that BioStem's addition signifies the importance of nurturing the MedTech industry within South Florida, as it fosters collaboration between scientific peers and educational opportunities for students.
BioStem Technologies is recognized for utilizing advanced processing methods to develop its range of high-quality allografts, with a commitment to improving lives through its cutting-edge healthcare solutions. For additional information, visit biostemtechnologies.com.
MWN-AI** Analysis
BioStem Technologies, Inc. (OTC: BSEM) has made a strategic move by acquiring land for its future headquarters at the Research Park at Florida Atlantic University in Boca Raton. This decision not only signals the company's intent to scale operations but also positions it among a community of innovation and research within the growing South Florida MedTech sector. The initiative is expected to generate up to 100 new jobs over five years, supported by up to $300,000 in economic incentives from local government.
From a market analysis perspective, this land acquisition denotes a bullish outlook for BioStem. By anchoring its headquarters in a well-established innovation hub, the company stands to benefit from proximity to university talent and collaborations that could prove pivotal for research and development. The Research Park is recognized for its cutting-edge facilities and has a proven track record in fostering the growth of technology and life sciences firms, making it an ideal environment for BioStem’s ambitious plans.
Investors should consider the implications of this expansion in light of BioStem’s focus on advanced wound care products, which have seen increasing demand driven by aging populations and rising chronic health conditions. The company’s unique BioRetain® processing method enhances its competitive edge in manufacturing allografts, positioning it favorably in a growing market.
However, potential investors should remain cautious and monitor relevant market trends, like shifts in healthcare regulations and the competitive landscape within the MedTech sector. The engagement with local economic incentives is a positive sign of community support, but successful execution of the expansion plan will be critical for sustained growth. For those looking to invest, this development presents an opportunity, but it warrants careful consideration of overarching market conditions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Future Relocation and Expansion to Create Up to 100 New Jobs Over 5 Years
City Approves Up to $300,000 in Economic Incentives to Rapidly Growing MedTech Business
POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the purchase of land for its future headquarters in the Research Park at Florida Atlantic University® in Boca Raton.
Under the terms of an agreement with the City, the Company will receive up to $300,000 in economic incentives for the creation of up to 100 jobs over a five-year period. The four-acre land parcel that the Company purchased will be the future home of all administrative offices, manufacturing, and distribution. BioStem has not yet set a timetable for its relocation to the new site.
“As we contemplate the long-term vision for BioStem, we anticipate the need to expand our operations in support of the growing demand for our advanced wound care products. Securing land at the Research Park provides the space for a centralized headquarters, access to talent and technology and attractive economic incentives,” said Jason Matuszewski, Chairman and CEO of BioStem Technologies. “While opportunities were presented to us by representatives of other states, we knew from the start that we wanted to remain in South Florida and continue to contribute greatly to the overall growth of the local life science industry. The Research Park location will place us among other technology innovators and in close proximity to a university with leading science and healthcare programs from which we can attract and train our highly specialized workforce. Furthermore, the City of Boca Raton has worked closely with us to understand and enable us to meet our real estate needs.”
The Research Park at Florida Atlantic University is home to technology companies and research-based organizations, serving as a hub for collaboration by connecting industry leaders and researchers, driving innovation and economic growth across South Florida. The location hosts Global Ventures, an international soft-landing center for second-stage technology companies as they expand into the U.S. market. Spanning 70 acres, the Research Park provides an environment where R&D companies can grow through access to university talent, state-of-the-art facilities, and tailored insights. Established in 1985, it is widely regarded as South Florida’s laboratory for new entrepreneurial ideas and technologies.
“The addition of BioStem Technologies to the Research Park’s community of innovation demonstrates the importance of our university research park for successful economic growth and long-term prosperity for South Florida,” said Andrew S. Duffell, president of the Research Park at Florida Atlantic. “The ability to collaborate with peer scientists close-by and to offer training opportunities for students an essential factor in developing a sustainable MedTech industry here.”
About BioStem Technologies:
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain ® processing method. BioRetain ® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap 2 ™, VENDAJE ® , VENDAJE AC ® , and VENDAJE OPTIC ® . Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on X and LinkedIn . To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE.
Investor Contact:
Philip Trip Taylor, Principal
Gilmartin Group
philip@gilmartinir.com
415-937-5406
Media Contact:
David Schull, President
Russo Partners
david.schull@russopartnersllc.com
858-717-2310
FAQ**
How does BioStem Technologies Inc BSEM plan to utilize the $300,000 in economic incentives, and what specific initiatives will these funds support in their expansion efforts?
What timeline can investors expect for BioStem Technologies Inc BSEM to relocate to the new headquarters at the Research Park, and how will this impact job creation?
Given the competitive landscape, what strategies will BioStem Technologies Inc BSEM implement to attract and retain a highly specialized workforce in South Florida?
How does BioStem Technologies Inc BSEM intend to leverage its proximity to Florida Atlantic University’s research capabilities to foster innovation in advanced wound care technology?
**MWN-AI FAQ is based on asking OpenAI questions about BioStem Technologies Inc (OTC: BSEM).
NASDAQ: BSEM
BSEM Trading
-10.85% G/L:
$5.1886 Last:
50,334 Volume:
$5.71 Open:
